Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance

Take a look inside the London 2014 Congress


Then register to join us
in Barcelona!


Search Abstracts by author or title
(results will display both Free Papers & Poster)

Results of accelerated corneal collagen cross-linking therapy for keratoconus at high altitude

Poster Details

First Author: M.Batur TURKEY

Co Author(s):    T. Yasar   E. Seven   M. Demir   F. Unal           

Abstract Details


To show efficacy and safety of crosslinking therapy for keratoconus treatment at high altitude ( 1727 meter above sea level, Van, Turkey.)


Yuzuncu Yil University Medical School Ophthalmology Department


In this prospective study we evaluated 88 eyes of 73 keratoconus patients which treated with accelerated corneal collagen crosslinking therapy. Mean age of patients was 18.36±4.25 years (between 12-33). The surgical technique included epi-off application riboflavin for 30 minutes and then 9 mW/cm2 UVA for ten minutes. Pre- and postoperative visual (LogMAR) acuity,keratometry,topography,pachymetry and examinations were recorded. Postoperative results were taken in 87 eyes at 1 month and in 59 eyes at 12 months visits.


There were no intraoperative complications in any patients. Epithelial healing completed at 2nd days in 70% eyes and at 4th days all eyes. Corneal haze occurred in 9 eyes and resolved within 1 month in 7 eyes. Central corneal thickness (CCT) was 443.57 μ±36.77 preoperatively and decreased to 365.76 μ±51.47 at 1 month,then it was 435.48 μ±49.34 at 12 months. MinK and MaxK values were 46.50±90,51.34±3.80 preoperatively and 46.89±2.88,51.79±3.68 at 1 month,then it was 46.83±2.94, 50.93±3.88 at 12 months


Oxygen represents the main driver of collagen crosslinking reaction.There is some studies mentioning about importance of oxygen in accelerated crosslinking treatment. Although oxygen saturation decreased at high altitude, our results shows efficacy of accelerated corneal collagen crosslinking therapy in keratoconus patients

Financial Disclosure:


Back to Poster listing